419540.Kq
419540.KQ is a South Korean company operating in the Advanced Medical Equipment & Technology industry, specializing in the design, development, and distribution of medical devices and equipment.
Business. 419540.KQ is a South Korean company operating in the Advanced Medical Equipment & Technology industry, specializing in the design, development, and distribution of medical devices and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
419540.KQ is a South Korean company operating in the Advanced Medical Equipment & Technology industry, specializing in the design, development, and distribution of medical devices and equipment.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating a conservative leverage position. However, the company has negative operating and free cash flows, with operating cash flow at -2.17 billion KRW and free cash flow at -427.27 million KRW, signaling liquidity constraints. The current ratio of 5.34 suggests strong short-term liquidity, but the negative net cash position after subtracting total debt raises concerns about the company's ability to meet long-term obligations.
Profitability metrics are weak, with a return on equity of -3.9% and a return on assets of -3.38%, both significantly below the industry median for Advanced Medical Equipment & Technology firms. The company reported a net loss of 699.12 million KRW and an operating loss of 1.096 billion KRW, indicating a challenging operating environment.
The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification in its revenue streams. This could expose the company to higher operational and market risks, particularly in a sector where innovation and regulatory compliance are critical.
Looking ahead, the company's growth trajectory is uncertain. The financial snapshot does not provide forward-looking revenue guidance, and the absence of a detailed outlook for the current or next fiscal year makes it difficult to assess future performance. The company's operating losses and negative cash flows suggest a need for strategic adjustments to achieve sustainable growth.
The risk assessment highlights medium liquidity risk and low dilution risk. The company's negative net cash position is a key flag, indicating potential challenges in maintaining operations without external financing. However, the low dilution risk suggests that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders.
Recent events, including filings and transcripts, are not detailed in the available data. The company's 10-K or equivalent disclosures would provide more insight into its strategic direction, operational challenges, and financial health. Investors should monitor upcoming filings for updates on the company's performance and plans to address its current financial situation.
- The company has a low debt-to-equity ratio but is experiencing negative operating and free cash flows.
- Profitability metrics are weak, with both return on equity and return on assets below zero.
- The company's revenue concentration and lack of segment data suggest a need for diversification.
- Liquidity risk is medium, and the company has a negative net cash position after subtracting total debt.
- The company's growth trajectory is uncertain, and forward-looking guidance is not available in the current data.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 419540.KQ Market data — financials · 2026-05-26